Traws Pharma (TRAW) to Release Quarterly Earnings on Monday

Traws Pharma (NASDAQ:TRAW) is projected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Traws Pharma to post earnings of ($7.00) per share for the quarter.

Traws Pharma Stock Performance

Shares of NASDAQ TRAW opened at $2.40 on Monday. Traws Pharma has a 1-year low of $2.02 and a 1-year high of $24.75. The business has a 50-day moving average of $4.73. The company has a market capitalization of $8.76 million, a P/E ratio of -0.02 and a beta of 1.42.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.